Bronchiectasis Market Size in the 7MM was ~USD 1,581.2 million in 2023, estimated DelveInsight

DelveInsight's "Bronchiectasis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of bronchiectasis, historical and forecasted epidemiology, as well as the bronchiectasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Bronchiectasis Market with DelveInsight's In-Depth Report @ Bronchiectasis Market Size [https://www.delveinsight.com/sample-request/bronchiectasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Bronchiectasis Market Report

* In November 2024:- Sanofi-A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis. ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
* In November 2024:- Boehringer Ingelheim- This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleaf or 1397-0013 Clairafly). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term.
* In November 2024:- Verona Pharma PLC- This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
* According to DelveInsight's epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques.
* In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases.
* Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases.
* Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases.
* Among the gender-specific cases of NCFB in the UK in 2023, there were approximately 130,486 cases for females and around 94,490 cases for males.
* In Japan in 2023, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to other pathogen, accounting for 46,600 cases.
* In 2023, among the 7MM, Japan had approximately 96,580 diagnosed prevalent cases of NCFB.
* In 2023, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of cystic fibrosis bronchiectasis, with approximately 41,566 cases, while Japan accounted for the least, with only 59 cases.
* Among the gender-specific cases of cystic fibrosis bronchiectasis in EU4 and the UK in 2023, there were approximately 17,081 cases for females and around 18,738 cases for males.
* Among the age-specific cases of cystic fibrosis bronchiectasis in Japan in 2023, there were approximately 24 cases for children and around 36 cases for adult.
* In 2023, the majority of etiology-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis in Japan were attributed to Staphylococcus aureus, accounting for 36 cases.
* The leading Bronchiectasis Companies such as Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL , and others.
* Promising Bronchiectasis Therapies such as CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302 , and others.

Stay ahead in the Bronchiectasis Therapeutics Market with DelveInsight's Strategic Report @ Bronchiectasis Market Outlook [https://www.delveinsight.com/sample-request/bronchiectasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bronchiectasis Epidemiology Segmentation in the 7MM

* Total diagnosed prevalent cases
* Gender-specific diagnosed prevalent cases
* Severity-specific diagnosed prevalent cases
* Etiology-specific diagnosed prevalent cases
* Microbiology of NCFB patients,
* Total diagnosed prevalent cases
* Gender-specific diagnosed prevalent cases
* Age-specific diagnosed prevalent cases
* Microbiology of cystic fibrosis bronchiectasis

Download the report to understand which factors are driving Bronchiectasis epidemiology trends @ Bronchiectasis Prevalence [https://www.delveinsight.com/sample-request/bronchiectasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bronchiectasis Emerging Drugs

* Brensocatib: Insmed/AstraZeneca

Brensocatib, an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), is being developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs), such as neutrophil elastase, during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with bronchiectasis, leading to plans for a New Drug Application (NDA) submission to the US FDA in late 2024. If approved, brensocatib is expected to launch in the US by mid-2025, followed by launches in Europe and Japan in the first half of 2026. In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with bronchiectasis at the CHEST 2024 Annual Meeting. Furthermore, the EMA approved a Pediatric Investigational Plan for brensocatib in bronchiectasis patients, and brensocatib has gained access to the PRIME scheme and Breakthrough Therapy Designation for adult bronchiectasis patients.

* Inhaled Colistimethate Sodium (CMS I-neb): Zambon

CMS I-neb is an investigational inhaled therapy for adults with bronchiectasis colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin, a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for infections like carbapenem-resistant P. aeruginosa. In September 2024, Zambon released the results of the Phase III PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicine journal. The Phase III PROMIS-I trial demonstrated a significant reduction in pulmonary exacerbation rates. Although the PROMIS-II trial was terminated early due to the pandemic, pre-pandemic data showed consistency with PROMIS-I outcomes. Zambon is working with regulatory authorities to expedite patient access. The US FDA has granted CMS I-neb Breakthrough Therapy Designation (BTD), as well as QIDP and Fast Track Designation (FTD).

* FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab) is a monoclonal antibody that targets the IL-5 receptor alpha on eosinophils, facilitating the recruitment of natural killer cells to induce apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with NCFB associated with eosinophilic inflammation (bronchiectasis + EI). According to clinicaltrials.gov, FASENRA completed Phase III clinical trials for this indication in April 2024.

Bronchiectasis Treatment Market

The treatment of bronchiectasis involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics, both oral and inhaled, are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides, often used for their anti-inflammatory properties, are beneficial in reducing exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids are used to address inflammation, although their role remains limited due to potential side effects. Mucolytic agents improve mucus clearance, and emerging anti-inflammatory agents targeting neutrophilic inflammation, such as DPP1 inhibitors, represent innovative approaches. Together, these drug classes form a comprehensive yet evolving treatment landscape for bronchiectasis, addressing its multifaceted pathophysiology.

Get In-Depth Knowledge on Bronchiectasis Market Trends and Forecasts with DelveInsight @ Bronchiectasis Treatment Market [https://www.delveinsight.com/sample-request/bronchiectasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Bronchiectasis Market Outlook

The market for bronchiectasis is poised for significant growth due to the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass a range of treatment options which includes medications, chest physical therapy, hydration, and in severe cases, oxygen therapy with inhaled antibiotics demonstrating efficacy in managing chronic bacterial infections and reducing exacerbation rates. Emerging therapies, such as Brensocatib, a Dipeptidyl Peptidase 1 (DPP1) inhibitor, and BI 1291583, a cathepsin C inhibitor, target neutrophilic inflammation through distinct mechanisms, thereby offering novel approaches to improve patient outcomes.

Bronchiectasis Therapeutics Market

Additionally, investigational therapies like CMS I-neb and monoclonal antibodies such as FASENRA and Itepekimab present further options by directly targeting specific inflammatory pathways associated with eosinophilic inflammation. The incorporation of non-pharmacological approaches, particularly Airway Clearance Techniques (ACTs), complements pharmacological regimens, enhancing mucus clearance and preventing infection. However, the market faces challenges, including a lack of consensus guidelines and under-researched therapies like mucolytics and hyperosmolar agents, which may hinder optimal patient management.

Unlock Strategic Insights with DelveInsight's Comprehensive Bronchiectasis Market Report @ Bronchiectasis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/bronchiectasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Bronchiectasis Market Report

* Coverage- 7MM
* Bronchiectasis Companies- Insmed, AstraZeneca, Zambon, Renovion, Haisco Pharmaceutical Group, Chiesi Farmaceutici S.p.A, Armata Pharmaceuticals, Verona Pharma, Sanofi, Regeneron Pharmaceuticals, Boehringer Ingelheim, CSL, and others.
* Bronchiectasis Therapies- CHF6333, Itepekimab (SAR440340), BI 1291583, Aztreonam lysine, HSK31858, RESP302, and others.
* Bronchiectasis Therapeutic Assessment: Bronchiectasis Current marketed and Lipodystrophy Emerging Therapies
* Bronchiectasis Market Dynamics: Bronchiectasis Market drivers and Bronchiectasis Market Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Patient Journey

9. Epidemiology and Patient Population

10. Emerging Drugs

11. Bronchiectasis: Market Analysis

12. Key Opinion Leaders' Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchiectasis-market-size-in-the-7mm-was-usd-15812-million-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity



This release was published on openPR.